Challenges including Obtaining Funding and Lack of Incentives for Researchers Hinder Antimicrobial Resistance Research

Superbugs & Superdrugs 2019

Superbugs & Superdrugs 2019

Issues in antimicrobial research including funding & motivating researchers to be explored at 21st Superbugs & Superdrugs conference in London, 18-19 March 2019

LONDON, LONDON, UNITED KINGDOM, November 12, 2018 / — After great success in both the UK and USA, SMi is delighted to announce the return of their Superbugs & Superdrugs conference for its 21st year running to London in March to help inspire, educate and support the global commitment to tackling multidrug-resistance amongst bacteria populations.

The two-day conference is set to give an in-depth analysis on the various strategies in place to support antimicrobial resistance research & development, the latest scientific advancements for tackling antimicrobial resistance, as well as potential novel candidates and alternatives to anti-microbials.

This year's event will not only provide the latest updates on antimicrobial research development, but will also focus on strategies companies use to assist development of new therapies. In addition, attendees will also learn about obtaining funding, and why there's a lack of incentives for researchers working in antimicrobial resistance research and development.

John Rex, Chief Medical Officer at F2G will be presenting at this year’s conference on “Anti-Infective Research: Funding, Filing and Finance”, where he will provide updates on funding initiatives, recent changes in the regulatory landscape, and payer models: evolving global discussions.

The 21st annual conference will host an international gathering of expert speakers from industry-leading organisations with the aim of sharing their combined experience and expertise about the ever-evolving threat of antibiotic resistance.


• Mair Powell, Senior Medical Officer, HPRA
• John Rex, Chief Medical Officer & Director, F2G
• David Cook, Chief Scientific Officer, Blueberry Therapeutics
• David Roblin, President of R&D, Chief Operating Officer and Chief Medical Officer, Summit Therapeutics
• Stephen A. Barat, Head of Pre-Clinical Research and Early Clinical Development, Scynexis
• Kazunori Maebashi, Senior Project Manager, Meiji Seika Pharma
• Chandrabali Ghose, CEO, Bioharmony Therapeutics
• Professor Eiríkur Steingrimsson, Co-founder, Akthelia Pharmaceuticals
• Chris Pickford, Head of Drug Discovery, Centauri Therapeutics
• Professor Christopher Schofield, Head of Organic Chemistry, Oxford University
• + many more!

Download the brochure on the event website to see the two-day agenda and speaker line-up at Book your place before 30th November to save £400.

Superbugs & Superdrugs
18th & 19th March 2019
Holiday Inn Kensington Forum, London, UK

—- END —-

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Maria Mandic
SMi Group
+44 207 827 6124
email us here

Source: EIN Presswire